Form 8-K - Current report:
SEC Accession No. 0001641172-25-000283
Filing Date
2025-03-24
Accepted
2025-03-24 16:10:15
Documents
15
Period of Report
2025-03-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 37123
2 ex99-1.htm EX-99.1 209577
3 ex99-1_001.jpg GRAPHIC 15280
  Complete submission text file 0001641172-25-000283.txt   468377

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ocx-20250324.xsd EX-101.SCH 3012
5 XBRL LABEL FILE ocx-20250324_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE ocx-20250324_pre.xml EX-101.PRE 24164
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3537
Mailing Address 15 CUSHING IRVINE CA 92618
Business Address 15 CUSHING IRVINE CA 92618 949-409-7600
Oncocyte Corp (Filer) CIK: 0001642380 (see all company filings)

EIN.: 271041563 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37648 | Film No.: 25764277
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)